Benzodiazepine Use Linked to Low Birth Defect Risk

A new study found no substantial increase in congenital malformation risks for babies exposed during the first trimester.

Updated on Oct. 12, 2026 in Pregnancy

Benzodiazepine Use Linked to Low Birth Defect Risk

Live Poll

Would you trust new medical findings to change your medication habits during pregnancy?

Researchers have found no significant link between first-trimester benzodiazepine exposure and major congenital malformations in live births. The findings were published in the Annals of Internal Medicine on October 12, 2026.

Why it matters

These results provide clarity for patients and clinicians evaluating the safety of benzodiazepines during pregnancy. Understanding these risks is vital for informed decision-making regarding psychiatric treatment for expectant mothers.

The study analyzed 2.5 million publicly insured and 1.75 million commercially insured pregnancies in the United States. Researchers observed a 2.1% prescription rate in public insurance and a 1.6% rate in commercial insurance.

The players

Brigham and Women's Hospital

This Boston-based teaching hospital is affiliated with Harvard Medical School and focuses on advanced clinical research.

Stanford University

Located in California, this university is a leading institution for scientific and medical research.

The details

The cohort study utilized Medicaid data from 2000 to 2018 and Merative MarketScan records from 2003 to 2020 to track live births. While general malformation risks remained low, the data showed higher risks for gastrointestinal or central nervous system issues when benzodiazepines were combined with mood stabilizers or antiepileptic drugs.

Medicaid data was collected from 2000 to 2018.
Merative MarketScan data was collected from 2003 to 2020.
The study was published in the Annals of Internal Medicine on October 12, 2026.

Culture Shift

This research reflects a growing emphasis on precision in maternal healthcare, moving away from generalized warnings toward data-backed safety profiles for common psychiatric medications. It aligns with the rigorous standards of the FDA's pregnancy exposure registry protocols to improve clinical transparency.

This research helps patients and doctors have more accurate conversations about balancing the benefits of psychiatric medication with potential developmental concerns. Readers should discuss any concerns about prescription exposure with their obstetrician or primary care provider.

The takeaway

Expectant mothers should continue to manage their mental health through open dialogue with medical professionals rather than making sudden changes to prescribed routines. Always seek individualized clinical advice before altering a medication regimen during pregnancy.